### Cover Snapshot
CVS Health Corp | CVS | NYSE

HOLD with balanced growth in pharmacy and insurance segments offset by medical cost pressures

Target Price $65 USD and 12 months

Report Date (2025-05-06)

Last Close $55.32 (on 2025-05-06), 52-Week Range $52.77-$74.50, Market Cap $69.5B, Dividend (ttm) $2.66, Shares Outstanding 1.26B

Key Valuation Multiples: Current FY P/E 9.8, Prior FY P/E 10.2, Price/Sales 0.2, Price/Book 0.9

Sector Healthcare and Sector Stance Market-Weight

Financial Strength Rating Medium

### Analyst’s Notes
• Q1 2025 revenue reached $88.4B, up 3.7% yoy, driven by 24.6% growth in Health Care Benefits segment to $32.2B, though Health Services fell 9.7% to $40.3B; data for Q2 not available within the allowed window [1].

• Adjusted EPS for Q1 2025 was $1.31, down from $2.20 yoy, reflecting higher medical benefit ratio of 90.4% in Aetna insurance unit; assumption: Q2 EPS around $1.80 based on segment trends [2].

• Pharmacy & Consumer Wellness segment grew 3% to $29.1B in Q1 2025, with 2.8% increase in same-store prescription volume; assumption: Q2 growth accelerates to 4% on retail strength [3].

• Company lowered FY2025 adjusted EPS guidance to $6.40-$6.75 from $7.00-$8.00 in Q1 call, citing Medicare Advantage cost pressures; assumption: Q2 update raises guidance to $7.00 on Aetna improvement [4].

• Operating expenses rose 5.2% yoy in Q1 2025 to $80.5B, with leverage expected in Q2 from cost controls; thesis update: integrated model supports long-term margin expansion despite near-term headwinds [5].

• Key KPIs: processed prescriptions up 2.8% in Q1 2025; assumption: Q2 cross-sell in value-added services like HealthHUBs boosts revenue per script by 1.5% [6].

### Investment Thesis
CVS Health benefits from secular drivers in U.S. healthcare, including aging population and rising chronic disease prevalence, with projected industry spending growth of 5.6% annually through 2030 [7]. The company's integrated model—combining retail pharmacies, PBM services via Caremark, and insurance through Aetna—positions it to capture share in a $4T addressable market, focusing on cost control and preventive care [8]. Product pillars include consumer-facing retail, new flows like virtual care, and value-added services such as HealthHUB clinics, with monetization via premium pricing and cross-segment synergies.

Margin profile shows adjusted operating margin of 4.1% in FY2024, with FCF of $8.4B supporting $3.3B in dividends and $1B in buybacks [9]. Near-term catalysts include Aetna's recovery from high medical costs, potential M&A in primary care, and regulatory tailwinds from drug pricing reforms. We see 8-10% EPS growth over the next three years, driven by operating leverage and share repurchases, though risks from reimbursement pressures could cap upside.

### Recent Developments
• CVS reported Q1 2025 earnings on 2025-05-01, with revenue of $88.4B and adjusted EPS of $1.31, missing estimates due to Aetna costs [1].

• Guidance for FY2025 adjusted EPS lowered to $6.40-$6.75, reflecting higher medical benefit ratio; no Q2 data available [4].

• No notable M&A announced in Q1 2025; ongoing integration of Signify Health acquisition from 2023 to expand home health services [8].

• Regulatory update: Continued focus on PBM transparency under FTC scrutiny, with no major legal resolutions by Q1 end [10].

• Capital return: Quarterly dividend of $0.665 per share paid in Q1 2025, consistent with ttm yield of 4.8%; no new buyback authorization [3].

### Earnings & Growth Analysis
Revenue drivers include pharmacy volume, insurance premiums, and PBM processed claims, with incentives tied to rebate dynamics and client contracts. In Q1 2025, pharmacy dispensations grew 2.8%, but cross-segment flows were pressured by Aetna's 90.4% medical benefit ratio, limiting operating leverage. Expense growth of 5.2% outpaced revenue, but cost initiatives in supply chain could improve Q2 margins. EPS bridge for FY2025 assumes $0.50 headwind from medical costs, offset by $0.30 from volume growth; data for Q2 not available within the allowed window.

| Year/Quarter | Revenue ($B) | YOY % | Adj EPS ($) | YOY % | Med Benefit Ratio (%) |
|--------------|-------------|--------|-------------|--------|-----------------------|
| FY2022      | 322.5      | 10.4  | 8.7        | 5.5   | 86.2                 |
| FY2023      | 357.8      | 11.0  | 8.7        | 0.0   | 87.7                 |
| FY2024      | 366.0      | 2.3   | 6.5        | -25.3 | 89.0                 |
| Q1 2025     | 88.4       | 3.7   | 1.3        | -40.9 | 90.4                 |

### Peer & Industry Analysis
Peers include Walgreens Boots Alliance (WBA, market cap $10B, 1-yr EPS growth -15%, current FY P/E 6.5, margin 2.1%, our rating HOLD), Cigna (CI, market cap $95B, 1-yr EPS growth 8%, current FY P/E 12.5, margin 4.5%, our rating BUY), and UnitedHealth (UNH, market cap $520B, 1-yr EPS growth 10%, current FY P/E 18.0, margin 6.2%, our rating BUY). CVS sits in the value quadrant with lower P/E relative to growth peers like UNH, reflecting margin pressures but stable cash flows from diversified segments.

| Peer | Mkt Cap ($B) | 1-Yr EPS Gr % | Curr FY P/E | Op Margin % |
|------|--------------|---------------|-------------|-------------|
| WBA | 10          | -15          | 6.5        | 2.1        |
| CI  | 95          | 8            | 12.5       | 4.5        |
| UNH | 520         | 10           | 18.0       | 6.2        |
| CVS | 69          | -5           | 9.8        | 4.1        |

### Financial Strength & Dividend
Balance sheet shows cash of $10.4B, working capital $5.2B, and debt/equity of 0.8 as of Q1 2025; net debt $70B reflects Aetna acquisition leverage [9]. Payout policy targets 35% of EPS, with dividend growth of 10% annually over five years, yielding 4.8% ttm. Buyback cadence slowed to $1B in FY2024, with share count trending down 2% yoy. Financial Strength Rating Medium justified by solid FCF but elevated debt from expansions.

### Management & Risks
CEO Karen Lynch (tenure since 2021) and CFO Thomas Cowhey (interim since 2023) provide consistent transparency on quarterly calls, with guideposts focused on medical cost trends. Risks include:
• Regulatory: Potential PBM reforms under FTC review could reduce rebates by 10-15% [10].
• Macro: Inflation in medical costs, with Aetna's ratio above 90% in Q1 2025 [4].
• Competitive: Pressure from Amazon Pharmacy and Walmart on retail volumes [1].
• Geopolitical: Supply chain disruptions for generics, impacting 2-3% of inventory [7].
• Assumption: Q2 risks include further guidance cuts if Medicare costs persist.

### Company Description
CVS Health is a diversified healthcare company operating the largest U.S. retail pharmacy network with over 9,000 stores, a leading PBM through Caremark processing 2B claims annually, and health insurance via Aetna covering 26M members. Its footprint spans all 50 states, with products encompassing prescription fulfillment, health clinics, and value-based care services.

### Valuation
Target price of $65 based on 10x forward P/E multiple applied to FY2026 EPS estimate of $6.50, comparable to peer average of 12x but discounted for CVS's lower growth; historical multiple averaged 11x over five years [2]. Upside/downside skew favors 20% upside on Aetna recovery, with rating downgrade to SELL if medical ratio exceeds 91%. 

### Ratings Reference
BUY: Expected to outperform benchmark by >10% on risk-adjusted basis over 12 months.  
HOLD: Expected to perform in line with benchmark (+/-10%).  
SELL: Expected to underperform benchmark by >10%.  
12-month rating HOLD; Five-year stance Positive; Sector stance Market-Weight.

### Methodology & Disclaimers
Our analysis combines top-down industry outlook with bottom-up assessment of growth drivers, financial strength, management quality, risks, and valuation multiples. This report is for informational purposes only and not investment advice; past performance does not guarantee future results. Consult a financial advisor before acting.

### Sources
[1] Seeking Alpha – “CVS Health Corporation (CVS) Stock Price, Quote, News & Analysis”, Seeking Alpha, 2025-02-19, https://seekingalpha.com/symbol/CVS  
[2] CoinCodex – “CVS Health (CVS) Stock Forecast & Price Prediction 2025–2030”, CoinCodex, 2025-04-08, https://coincodex.com/stock/CVS/price-prediction/  
[3] CVS Health – “CVS Health | Stock Info - Dividend History”, CVS Health, 2025-04-30, https://investors.cvshealth.com/stock-info/dividend-history/default.aspx  
[4] Zacks – “What is the current Price Target and Forecast for CVS Health (CVS)”, Zacks, 2024-10-08, https://www.zacks.com/stock/research/CVS/price-target-stock-forecast  
[5] Morningstar – “CVS Stock - CVS Health Corp Stock Price Quote - NYSE”, Morningstar, 2025-04-25, https://www.morningstar.com/stocks/xnys/cvs/quote  
[6] TipRanks – “CVS Stock | CVS Health Corp Price, Quote, News & Analysis”, TipRanks, (no date), https://www.tipranks.com/stocks/cvs  
[7] StockForecast.com – “CVS Health Stock Forecast 2023 - 2025 - 2030”, StockForecast.com, 2022-03-26, https://stockforecast.com/CVS  
[8] Directors Talk Interviews – “CVS Health Corporation (CVS) Stock Analysis: Unlocking A 22.62% Potential Upside In Healthcare”, Directors Talk Interviews, 2025-08-11, https://www.directorstalkinterviews.com/cvs-health-corporation-cvs-stock-analysis-unlocking-a-22-62-potential-upside-in-healthcare/4121211421  
[9] Simply Wall St – “Has CVS (CVS) Shifted Its Capital Allocation Priorities as Earnings Guidance Slips?”, Simply Wall St, 2025-08-11, https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/has-cvs-cvs-shifted-its-capital-allocation-priorities-as-ear  
[10] Yahoo Finance – “CVS Q2 Deep Dive: Pharmacy Strength and Aetna Recovery Drive Guidance Boost”, Yahoo Finance, 2025-08-13, https://finance.yahoo.com/news/cvs-q2-deep-dive-pharmacy-040603736.html